A COPD biologic that does not ask about the eosinophil count

Design

two replicate randomised, placebo-controlled phase 3 trials (OBERON, TITANIA), 52 weeks, no eosinophil entry criterion

Population

1,750 adults with COPD, current or former smokers, exacerbation in the previous year despite stable inhaled maintenance therapy

Primary outcome

annualised rate of moderate or severe exacerbations over 52 weeks among former smokers

Effect

OBERON rate ratio 0.71 (95% CI 0.57-0.88), TITANIA 0.66 (0.55-0.80); overall population 0.70 (0.58-0.85) and 0.71 (0.59-0.84)

Two replicate phase 3 trials, OBERON and TITANIA, enrolled adults with COPD who were current or former smokers and had exacerbated in the previous year despite stable inhaled maintenance therapy. Crucially, there was no eligibility criterion for blood eosinophils. Patients received subcutaneous tozorakimab 300 mg, an interleukin-33 antibody, or placebo every four weeks for 52 weeks.

In the overall population, annualised moderate or severe exacerbations fell from 2.00 to 1.41 in OBERON (rate ratio 0.70, 95% CI 0.58-0.85) and from 2.03 to 1.44 in TITANIA (rate ratio 0.71, 0.59-0.84). The primary endpoint, in former smokers, showed the same: 1.90 to 1.34 (0.71, 0.57-0.88) and 2.07 to 1.37 (0.66, 0.55-0.80). Adverse events were no commoner than placebo in either trial.

Every biologic that has worked in COPD so far has worked in the eosinophilic subgroup, which leaves out most patients. Two replicate trials agreeing to two decimal places, in an unselected population, is a stronger signal than one larger trial would be. The generalist consequence is simple: the COPD patient who keeps exacerbating on triple therapy and has a normal eosinophil count is no longer automatically out of options, and is worth a respiratory opinion rather than another course of prednisolone.

• Record exacerbation frequency in the notes — it is the entry criterion for every trial in this space
• Check that inhaler technique and adherence are genuinely optimised before escalating; most 'refractory' COPD is not
• A normal eosinophil count no longer rules out a biologic pathway
• Cost and availability will decide this in India long before eligibility does

Why it matters

It is the first COPD biologic signal that does not depend on selecting patients by eosinophil count.

Don't overread it

Exacerbation rate over 52 weeks is not mortality or lung function, and neither trial was designed to show those.

The statistics, in plain English

A rate ratio of 0.70 on an annualised exacerbation rate means roughly three exacerbations become two — about 0.6 fewer per patient per year, which is a meaningful reduction in a disease where each exacerbation costs lung function. Two independent trials producing 0.70 and 0.71 is the reason to believe the estimate: replication does more for confidence than a narrow interval in a single trial.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.